Reach Us +1 850 900 2634

International Journal of Cardiovascular ResearchISSN: 2324-8602

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, Int J Cardiovasc Res Vol: 2 Issue: 2

The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine

David Jang1*, Sean Donovan2, Theodore Bania2, Lewis Nelson3, Robert Hoffman3 and Jason Chu4
1New York University School of Medicine, USA
2Department of Emergency Medicine St. Luke’s-Roosevelt Hospital Center, USA
3Department of Emergency Medicine New York University School of Medicine Bellevue Hospital Center New York, New York, USA
Corresponding author : David Jang
Assistant Professor, New York University School of Medicine, USA
E-mail: [email protected]
Received: February 28, 2013 Accepted: March 04, 2013 Published: March 29, 2013
Citation: Jang D, Donovan S, Bania T, Nelson L, Hoffman R, et al. (2013) The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine. Int J Cardiovasc Res 2:2. doi:10.4172/2324-8602.1000121

Abstract

The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine

Cardiovascular drug poisoning remains a leading cause of fatality. Within this class, calcium channel blockers(CCBs) account for the majority of deaths. CCBs are typically categorized as dihydropyridines (i.e. amlodipine or nifedipine) versus the non-dihydropyridine (i.e. verapamil and diltiazem) which are the most potent and once considered the CCB type responsible for all CCB-related deaths. Most recently, dihydropyridine deaths have increased. While there are established models of nondihydropyridine poisoning there currently are no established experimental models of dihydropyridine poisoning.

Keywords: Cardiovascular drug; LD50; Dihydropyridine

Track Your Manuscript

Share This Page

Media Partners